Few decisions in drug development carry the regulatory weight of choosing where to make a scheduled product. When you outsource controlled substance manufacturing, you are not simply selecting a production partner. You are entering a program governed by two federal authorities at once: the FDA, through cGMP requirements, and the Drug Enforcement Administration, through the Controlled Substances Act. Not every contract manufacturer is licensed, equipped, or experienced enough to operate at that second layer, which is why your due diligence must go well beyond standard CDMO criteria.
This guide walks you through the requirements that define DEA Schedule I-V pharmaceutical manufacturing and the questions you should ask before signing with any partner.
Article Contents
Why Controlled Substance Programs Demand More
A standard oral solid program adheres to cGMP. A scheduled program is subject to cGMP and a separate body of DEA regulations that govern registration, production limits, physical security, and recordkeeping. Each schedule, from I through V, carries its own controls, and the stakes for noncompliance include lost registration and criminal exposure. The earlier you understand these obligations, the more accurately you can plan your timeline and budget. Treating DEA compliance as an afterthought is the most common way sponsors lose months they cannot recover.
DEA Registration Categories
DEA registration is activity-specific, not company-wide. A facility must hold the correct registration for each function it performs, whether that is manufacturing, distribution, or analytical testing. A partner cleared to manufacture a scheduled product is not automatically cleared to test it, and gaps between those registrations can force off-site transfers that introduce both risk and delay. The most capable DEA-controlled-substance CDMO holds the full set of registrations under one roof, so your material never has to leave a secured, licensed environment.
The Annual Quota System
For Schedule I and II substances, the DEA controls how much material may be procured and produced through the controlled substance quota process DEA administers each year. Your manufacturer applies for a quota, and any increase must be requested and approved before production can scale. Approvals typically take about four weeks, and that window cannot be accelerated, no matter how urgent your launch. Unused quota does not roll forward, so planning is everything. An experienced partner forecasts your needs with you and files early, which is one of the practical advantages of working with a team that understands Schedule II drug manufacturing outsourcing from the inside.
Vault and Cage Storage by Schedule
Physical security requirements escalate with schedule, and the DEA specifies vault construction, alarms, access controls, and recordkeeping in detail. When evaluating controlled-substance vault storage, pharma sponsors should confirm both the capacity and the classification of a partner's secured space. UPM operates more than 15,800 square feet of DEA-approved vault space, split between 7,200 square feet on-site and 8,300 square feet off-site, supporting Schedule II-V materials and listed chemicals. You can review the specific construction and recordkeeping standards behind those requirements in our DEA-approved vault space guidelines.
Chain of Custody During Manufacturing
Security does not stop at the vault door. Every gram of scheduled material must be accounted for as it moves through dispensing, blending, compression, coating, and packaging. Reconciliation at each step, documented and witnessed, is what allows your partner to demonstrate that nothing was diverted. The controls UPM applies to controlled-substance handling include rigorous staff training, segregated workflows, and continuous accountability measures designed to satisfy DEA scrutiny during unannounced inspections. Many scheduled compounds are also highly potent, so the same discipline often runs alongside the containment practices used in high-potent handling.
Due Diligence Before You Sign
Once you understand the requirements, your selection criteria become clear. Look for a pharmaceutical contract manufacturer that is DEA-registered across manufacturing, distribution, and analytical testing, with a long, documented relationship with the agency. Ask about audit history, because a record of clean DEA inspections tells you more than any capability sheet. Confirm that analytical work for scheduled substances is performed in-house under proper registration, supported by the partner's formulation and analytical development capabilities, so your program never depends on an off-site technology transfer midstream. Finally, weigh the strength of the partner's quality and regulatory support function, since the documentation behind a scheduled program is as consequential as the manufacturing itself.
A partner that can demonstrate end-to-end capability, a clean compliance history, and decades of proactive DEA engagement turns one of the most demanding categories in contract manufacturing into a predictable, well-governed program. That is the standard to hold your shortlist to when you outsource controlled substance manufacturing.
FAQs
Does a sponsor company need its own DEA registration if it is outsourcing manufacturing of a controlled substance to a licensed CDMO?
In most cases, yes. The CDMO holds the registrations required to manufacture, store, and test your product, but as the sponsor and owner of the material, you will typically need your own DEA registration appropriate to your role, such as importer, distributor, or researcher. The right registration depends on how you take title to and move the finished product, and your CDMO and DEA counsel can confirm the correct category for your program.
What happens to unused controlled substance quota at the end of a calendar year, and can it roll over to the next year?
Unused quota does not roll over. DEA quotas are granted on a calendar-year basis, and any allotment not used expires at year's end. Because of this, your manufacturer should forecast demand carefully, and file quota and increase requests early so that production is never held up by an expired or insufficient allocation.
How long does it typically take to receive a DEA quota for a Schedule II substance when starting a new outsourced manufacturing program?
Plan for roughly four weeks of DEA processing time for a quota request, and build that window into your project timeline from the start. It cannot be expedited, so early forecasting and application are the only reliable ways to protect your schedule.
CONTACT US
Partner With a Proven Controlled Substance CDMO
If your next program involves a scheduled compound, the partner you choose will shape your timeline, your compliance posture, and your path to commercialization. UPM brings more than two decades of controlled substance experience, a full set of DEA registrations, 15,800 square feet of DEA-approved vault space, and an analytical lab registered for Schedule I-V work, all under one roof in Bristol, Tennessee. To talk through your project and how to outsource controlled-substance manufacturing without falling into avoidable compliance gaps, contact our team to start the conversation.
Quality and Regulatory Support Contact UPM Pharmaceuticals
